Core Viewpoint - Yunnan Watson Bio-Technology Co., Ltd. has signed an amendment to the exclusive sublicense agreement with Notitia Biotechnologies Company to expand its development and commercialization rights in the field of gut microbiota health targeting non-patient populations, aligning with national health strategies [1][2]. Group 1: Agreement Details - The amendment allows Watson Bio to exclusively develop, manufacture, and commercialize core microbiota analysis, targeted transplantation, and nutritional formula technologies in mainland China, Hong Kong, and Macau for non-patient populations [1][2]. - The agreement aims to establish a dual-track layout of "disease treatment intervention" and "chronic disease prevention + health nutrition," providing comprehensive health solutions [1][2]. - The amendment does not constitute a related party transaction or a major asset restructuring as defined by regulations [1][2]. Group 2: Financial Terms - Watson Bio will pay Notitia a total of $1,500,000 in license issue fees, with specific payment schedules outlined [3][4]. - Ongoing royalties will be 6.5% of net sales from sublicensed products, with minimum royalty payments established for subsequent years [4][5]. - Milestone payments are structured based on the achievement of specific regulatory approvals and sales targets, with amounts ranging from $500,000 to $30,500,000 [5][6]. Group 3: Company Impact - The signing of the amendment is not expected to significantly impact the company's operating performance for the current year, as the financial arrangements are closely tied to product development progress [6]. - The payment structure is designed to ensure efficient use of funds and alleviate short-term financial burdens on the company [6].

人民财讯7月30日电，沃森生物（300142）7月30日晚间公告，公司与美国Notitia Biotechnologies Company(简称"Notitia")已于2025年5月23日签署了一份《微生态健康靶向技术独家再许可协议》， 就"患者领域"内进行了再许可安排；双方有意扩大合作范围至"非患者领域"，并拟通过本修正案对《再 许可协议》进行修订，以涵盖在非患者领域内相关知识产权及专有技术的再许可安排。根据修正案， Notitia将其与美国新泽西州立罗格斯大学签署的上游许可协议所获得的核心菌群分析、菌群靶向移植及 营养配方技术授予公司在中国内地、香港和澳门地区针对非患者人群进行独占开发、制造及商业化的权 利。 ...